Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

被引：3
|
作者：
Dumbrava, Ecaterina Elena
Shapiro, Geoffrey
Bendell, Johanna C.
Yap, Timothy A.
Jeselsohn, Rinath
Lepley, Denise M.
Hurley, Sabrina
Lin, Kevin K.
Liao, Michelle
Habeck, Jenn
Enke, Aaron
Hamilton, Erika P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] Clovis Oncol Inc, Boulder, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3102
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
    Hendrickson, Andrea Elisabeth Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Fleix
    Flatten, Karen S.
    Poirier, Guy G.
    Lensing, Janet
    Erlichman, Charles
    Kaufmann, Scott H.
    Haluska, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1568 - 1576
  • [3] Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
    Yoichi Naito
    Yasutoshi Kuboki
    Masafumi Ikeda
    Kenichi Harano
    Nobuaki Matsubara
    Shigeyuki Toyoizumi
    Yuko Mori
    Natsuki Hori
    Takashi Nagasawa
    Takahiro Kogawa
    Investigational New Drugs, 2021, 39 : 1568 - 1576
  • [4] Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC)
    Oaknin, A.
    Oza, A.
    Tinker, A. V.
    Ray-Coquard, I.
    Coleman, R.
    O'Malley, D.
    Shapira-Frommer, R.
    Leary, A.
    Chen, L. M.
    Provencher, D.
    Ma, L.
    Brenton, J.
    Balmana, J.
    Giordano, H.
    Maloney, L.
    Goble, S.
    Rolfe, L.
    McNeish, I.
    Swisher, E.
    Kristeleit, R. S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S95 - S95
  • [5] Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
    Liao, Mingxiang
    Watkins, Simon
    Nash, Eileen
    Isaacson, Jeff
    Etter, Jeff
    Beltman, Jeri
    Fan, Rong
    Shen, Li
    Mutlib, Abdul
    Kemeny, Vendel
    Papai, Zsuzsanna
    van Tilburg, Pascal
    Xiao, Jim J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 765 - 775
  • [6] Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
    Mingxiang Liao
    Simon Watkins
    Eileen Nash
    Jeff Isaacson
    Jeff Etter
    Jeri Beltman
    Rong Fan
    Li Shen
    Abdul Mutlib
    Vendel Kemeny
    Zsuzsanna Pápai
    Pascal van Tilburg
    Jim J. Xiao
    Investigational New Drugs, 2020, 38 : 765 - 775
  • [7] Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
    Kristeleit, R. S.
    Oza, A. M.
    Oaknin, A.
    Aghajanian, C.
    Tinker, A. V.
    Tredan, O.
    O'Malley, D. M.
    Leary, A.
    Konecny, G. E.
    Lorusso, D.
    Weberpals, J. I.
    Goble, S.
    Maloney, L.
    Cameron, T.
    Swisher, E.
    McNeish, I. A.
    Shapira-Frommer, R.
    Ledermann, J. A.
    Coleman, R. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 409 - +
  • [8] Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
    Tan, A. R.
    Toppmeyer, D.
    Stein, M. N.
    Moss, R. A.
    Gounder, M.
    Lindquist, D. C.
    Ji, J. J.
    Chen, A. P.
    Egorin, M. J.
    Kiesel, B.
    Beumer, J. H.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
    Hendrickson, Andrea E. Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Felix
    Kayode, Olumide
    Flatten, Karen S.
    Harrell, Maria I.
    Swisher, Elizabeth M.
    Poirer, Guy G.
    Satele, Daniel
    Allred, Jake
    Lensing, Janet L.
    Chen, Alice
    Ji, Jiuping
    Zang, Yiping
    Erlichman, Charles
    Haluska, Paul
    Kaufmann, Scott H.
    CLINICAL CANCER RESEARCH, 2018, 24 (04) : 744 - 752
  • [10] Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
    Jens Samol
    Malcolm Ranson
    Edwina Scott
    Euan Macpherson
    James Carmichael
    Anne Thomas
    James Cassidy
    Investigational New Drugs, 2012, 30 : 1493 - 1500
12345